MET and hepatocellular carcinoma: Chen et al. (2019) found lncRNA HIF1A-AS2 might target in hypoxia-mediated therapeutic resistance via HMGA1/p53 pathway in bladder cancer. Further, lncRNAs also have been identified as regulators of sorafenib resistance. Activating the Akt pathway, lncRNA SNHG1 induces sorafenib resistance in HCC cells (Li et al., 2019b). Sponging miR-335, lncRNA NEAT1 suppresses the c-MET and AKT pathway thereby increasing HCC cells’ sensitivity to sorafenib (Chen & Xia, 2019).